21-position Substituted Patents (Class 514/181)
  • Patent number: 10183030
    Abstract: The present invention provides certain cortexolone derivatives of formula (I) and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. Another aspect of the invention relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of said pharmaceutical compositions as antitumor medicinal products.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: January 22, 2019
    Assignee: COSMO TECHNOLOGIES LIMITED
    Inventor: Mara Gerloni
  • Patent number: 9504858
    Abstract: Provided are compositions, e.g., oral and personal care products, comprising (i) a zinc amino acid halide complex, and (ii) cysteine in free or in orally or cosmetically acceptable salt form, together with methods of making and using the same.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: November 29, 2016
    Assignee: Colgate-Palmolive Company
    Inventors: Shaotang Yuan, Long Pan, Laurence D. Du-Thumm
  • Patent number: 9370540
    Abstract: A method for providing a K2-enriched FU-LING extract is provided. The method comprises the following steps: (a) mixing a FU-LING with a solvent to provide a first mixture; (b) alkalizing the first mixture to provide a second mixture; (c) acidifying the second mixture to provide a third mixture, (d) alkalizing the third mixture to provide a fourth mixture, wherein the fourth mixture has a pH value of more than 7; and (e) neutralizing the forth mixture, wherein the K2 is at least one of tumulosic acid, dehydrotumulosic acid, polyporenic acid C and 3-epi-dehydrotumulosic acid.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: June 21, 2016
    Assignee: SINPHAR PAHRMACEUTICAL CO., LTD.
    Inventors: Hang-Ching Lin, Hsin-Wen Huang, Shih-Min Lu
  • Patent number: 9364488
    Abstract: Methods for effective remyelination in patients are disclosed comprising treating the patient with an androgen receptor ligand which exerts binding to androgen receptors and elicits androgen-receptor-induced biological responses at a dosage sufficient to induce remyelination. The androgen compound preferably comprises MENT in an androgen targeting both androgen and estrogen receptors, and the methods include combining the androgen compound with a progestin compound in order to provide both contraception in men and treatment for neurodegeneration.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: June 14, 2016
    Assignee: The Population Council, Inc.
    Inventors: Regine Sitruk-Ware, Michael Maria Helmut Schumacher, Abdelmouman Ghoumari, Said Ghandour, Rashad Hussain, Bartosz Bielecki
  • Patent number: 9222118
    Abstract: The invention provides methods to identify agents useful to prevent, inhibit or treat viral infections, e.g. filovirus infections, as well as compositions having one or more agents to prevent, inhibit or treat viral infection.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: December 29, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Yoshihiro Kawaoka, Shinji Watanabe, Yasuko Hatta
  • Patent number: 9046534
    Abstract: Methods and systems for identifying and treating a patient suspected of having a tumor susceptible to growth inhibition by anti-progestins are provided. The degree of focal distribution of the progesterone receptor can be used to identify tumors susceptible to treatment with anti-progestin therapy.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: June 2, 2015
    Assignee: INVIVIS PHARMACEUTICALS INC.
    Inventor: Erard Gilles
  • Publication number: 20150133415
    Abstract: Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component. The composition is in a fluid form before placement in the interior of an eye, and becomes less fluid after the composition is placed in the eye to form an extended or delayed release drug delivery element or system. The drug delivery element is formed by the dissipation of the solvent from the composition when the composition is placed in the interior of an eye. One example of a composition includes triamcinolone acetonide as a therapeutic agent. A method of treating an ophthalmic condition, or otherwise improving or enhancing vision of a patient, comprises placing the fluid composition in the interior of the eye. The method may be practiced by injecting the fluid composition into the interior of the eye.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 14, 2015
    Inventor: Scott M. Whitcup
  • Patent number: 9017725
    Abstract: Topical drug delivery systems for ophthalmic use including mixed nanomicellar formulations of water-insoluble drugs and methods of treating diseases affecting the posterior ocular segments are disclosed. In an embodiment, an aqueous ophthalmic solution includes nanomicelles in a physiologically acceptable buffer, having a pH of 5.0 to 8.0, wherein a corticosteroid at a concentration from about 0.01% w/v to about 1.00% w/v is solubilized through entrapment in a mixed micellar hydrophobic core with a corona composed of hydrophilic chains extending from the hydrophobic core, wherein the nanomicelles comprise vitamin E TPGS at a concentration ranging from about 3.0% w/v to about 5.0% w/v stabilized with octoxynol-40 at a concentration ranging from about 1.0% w/v to about 3.0% w/v.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: April 28, 2015
    Assignee: Aurinia Pharmaceuticals Inc.
    Inventors: Ashim K. Mitra, Poonam R. Velagaleti, Ulrich M. Grau
  • Publication number: 20150104515
    Abstract: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion.
    Type: Application
    Filed: May 15, 2014
    Publication date: April 16, 2015
    Applicant: Massachusetts Institute of Technology
    Inventors: David A. Edwards, Robert S. Langer, Rita Vanbever, Jeffrey D. Mintzes, Jue Wang, Donghao Chen
  • Patent number: 9006223
    Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: April 14, 2015
    Assignees: The Hospital for Sick Children, McMaster University
    Inventors: Don J Mahuran, Michael B Tropak, Justin D Buttner, Jan E Blanchard, Eric D Brown
  • Publication number: 20150056286
    Abstract: The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: November 7, 2014
    Publication date: February 26, 2015
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Douglas Hovey, John Pruitt, Tuula Ryde
  • Patent number: 8951994
    Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: February 10, 2015
    Assignees: The Hospital for Sick Children, McMaster University
    Inventors: Don J Mahuran, Michael B Tropak, Justin D Buttner, Jan E Blanchard, Eric D Brown
  • Patent number: 8940321
    Abstract: The present invention relates to compositions and methods useful for the treatment of ear disorders, administered to a treated ear in the form of a foam or a mousse. Administering a medicament in such forms will increase the residence time of the medicament in the ear canal, provide relatively uniform distribution of the composition, and can increase the penetration of the active pharmaceutical ingredient in the affected area, may release active substances slowly, enhance treatment effectiveness, increase compliance and is more convenient to use than currently available ear medications. The administration in the form of a foam or a mousse may preferably be provided as a metered dose, of a volume suitable to fill the ear canal.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: January 27, 2015
    Assignee: Otic Pharma Ltd.
    Inventor: Eran Eilat
  • Patent number: 8937059
    Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: January 20, 2015
    Assignees: The Hospital for Sick Children, McMaster University
    Inventors: Don J Mahuran, Michael B Tropak, Justin D Buttner, Jan E Blanchard, Eric D Brown
  • Publication number: 20150018322
    Abstract: Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 15, 2015
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • Patent number: 8933062
    Abstract: The invention relates to nitrooxyderivative of corticosteroids of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof R—(Z)a—Rx??(I) wherein R is the corticosteroid residue of formula (II): wherein: R1 is OH, R2—CH3, or R1 and R2 are taken together to form a group of formula (III) R3 is Cl or F; R4 is H or F; wherein R1, R2, R3 and R4 can be linked to the correspondent carbon atoms of the steroidal structure in position ? or ?; with the proviso that: when R1 and R2 are the group of formula (III) then R3 is F and R4 is H or F; The compounds are useful in the treatment of respiratory diseases, inflammatory diseases, dermatological diseases and ocular diseases.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: January 13, 2015
    Assignee: Nicox S.A.
    Inventors: Francesca Benedini, Stefano Biondi, Ennio Ongini
  • Publication number: 20140374516
    Abstract: Disclosed is a process for the preparation of drug/carrier inclusion composites which involves co-grinding the mixture of drug and carrier powders in a fluid-jet mill, in particular one using air or nitrogen as the fluid, which is suitably modified to allow mechanical fusion of the powders.
    Type: Application
    Filed: January 25, 2013
    Publication date: December 25, 2014
    Applicant: MICRO-MACINAZIONE S.A.
    Inventors: Fabio Carli, Piero Iamartino, Milko Leone
  • Patent number: 8877164
    Abstract: Aerosol solution formulation for use in an aerosol inhaler which includes at least one active ingredient selected from 20-ketosteroids and quinolinone derivatives, a propellant containing a hydrofluoroalkane, a cosolvent, and a specific amount of a sequestering agent that stabilizes the formulation. By way of example, the stabilizing agent may be phosphoric acid or sulphuric acid.
    Type: Grant
    Filed: February 24, 2006
    Date of Patent: November 4, 2014
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: David Andrew Lewis, Brian John Meakin, Maurizio Delcanale, Fausto Pivetti
  • Publication number: 20140309203
    Abstract: Phytoecdysones to avoid weight gain in obese mammals previously having undergone a hypocaloric weight-loss diet. The phytoecdysones are added to a food composition. The phytoecdysones can be from plants, such as quinoa.
    Type: Application
    Filed: November 12, 2012
    Publication date: October 16, 2014
    Inventors: Rene Lafont, Karine Clement, Salwa Rizkalla, Stanislas Veillet, Anne-Sophie Foucault, Waly Dioh
  • Publication number: 20140303132
    Abstract: The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure wherein R is —C13H25O or —C14H27O. One or both of the esters can be present in the pharmaceutical composition. The composition is formulated such that upon single dose administration to a group of human subject, the composition provides a mean serum testosterone Cavg t12-t24 that is within about 35% to about 70% of the mean serum testosterone Cavg t0-t24.
    Type: Application
    Filed: May 30, 2014
    Publication date: October 9, 2014
    Inventors: Satish Kumar Nachaegari, Chandrashekar Giliyar, Raj Patel, Chidambaram Nachiappan, Srinivasan Venkateshwaran, Mahesh V. Patel
  • Publication number: 20140296199
    Abstract: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
    Type: Application
    Filed: June 12, 2014
    Publication date: October 2, 2014
    Inventors: Robert E. Dudley, Panayiotis P. Constantinides
  • Publication number: 20140274986
    Abstract: A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.
    Type: Application
    Filed: May 29, 2014
    Publication date: September 18, 2014
    Applicant: Clarus Therapeutics, Inc.
    Inventors: Robert E. Dudley, Panayiotis P. Constantinides
  • Publication number: 20140255473
    Abstract: The present invention is directed to steroid hormone delivery systems and methods of preparing the same. In particular, the steroid hormone delivery systems provided include a primary construct having one or more hydrophobic steroid hormone esters in the form of a liposome, a lipid particle, a micelle, an emulsion or a niosome which is then formulated into a secondary construct for administration. Exemplary secondary constructs include a film for sublingual or buccal administration.
    Type: Application
    Filed: May 19, 2014
    Publication date: September 11, 2014
    Applicant: MONOSOL RX, LLC
    Inventors: Eric Dadey, Alexander Mark Schobel
  • Patent number: 8828440
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: September 9, 2014
    Assignee: Flexion Therapeutics, Inc.
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Patent number: 8809350
    Abstract: The present invention relates to the use of an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease associated with antinuclear antibodies, wherein the inhibitor of CDK2 and/or CDK7 and/or CDK9 or pharmaceutically acceptable salt thereof is administered in an amount sufficient to down-regulate the levels of antinuclear antibodies. A further aspect of the invention relates to a combination comprising an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, and methylprednisolone, and its use in the treatment of diseases associated with antinuclear antibodies, such as SLE.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: August 19, 2014
    Assignee: Cyclacel Limited
    Inventors: Ariela Benigni, Carla Zoja, Giuseppe Remuzzi, Athos Gianella-Borradori
  • Patent number: 8785427
    Abstract: The present invention refers to a new enzymatic process for obtaining 17?-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17?,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone 17?-propionate and 9,11-dehydro-cortexolone 17?-butanoate.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: July 22, 2014
    Assignee: Cosmo Dermatos Srl
    Inventors: Ajani Mauro, Moro Luigi
  • Publication number: 20140186278
    Abstract: An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficulty soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”.
    Type: Application
    Filed: September 19, 2013
    Publication date: July 3, 2014
    Inventor: Patrick Franke
  • Publication number: 20140179655
    Abstract: The present invention relates to a composition, particularly a pharmaceutical composition comprising a testosterone derivative having a log P of at least 5 and a vehicle, wherein the vehicle comprises a fat component in an amount sufficient to achieve lymphatic absorption in a mammal, wherein the fat component comprises a mono- or triglyceride of long chain fatty acids
    Type: Application
    Filed: December 19, 2013
    Publication date: June 26, 2014
    Applicant: Solural Pharma ApS
    Inventor: Bent Højgaard
  • Publication number: 20140179654
    Abstract: The present invention refers to a new enzymatic process for obtaining 17?-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17?,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone 17?-propionate and 9,11-dehydro-cortexolone 17?-butanoate.
    Type: Application
    Filed: November 7, 2013
    Publication date: June 26, 2014
    Applicant: Cosmo SPA
    Inventors: Mauro Ajani, Luigi Moro
  • Publication number: 20140128357
    Abstract: The disclosure relates to methods of using brassinosteroid compounds, including those defined by formula I or a derivative thereof, for inducing an anabolically favorable state for growth, repair, and maintenance of skeletal muscle and skin.
    Type: Application
    Filed: December 13, 2011
    Publication date: May 8, 2014
    Applicant: Rutgers University
    Inventors: Ilya Raskin, Debora Esposito, Slavko Komarnytsky, Thirumurugan Rathinasabapathy, Leonel Rojo Castillo
  • Publication number: 20140128345
    Abstract: Described are drug delivery systems incorporating electrospun fibers that comprise and deliver physicochemically diverse drug compounds. Such fibers provide significant advantages in drug agent release, such as adaptability for solid dosage delivery to mucosal tissues. This is in addition to allowing for controlled drug release. Systems and methods for large-scale electrospinning productivity are described, including novel microarchitectures allowing for variable pharmacokinetics in drug release.
    Type: Application
    Filed: November 6, 2013
    Publication date: May 8, 2014
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Kim A. Woodrow, Cameron Ball, Anna Blakney, Emily Krogstad, Huarong Nie
  • Patent number: 8685951
    Abstract: The present invention provides compositions and methods for cytoprotection. In particular, it provides zinc chelate compositions comprising at least one zinc ion and at least one aminothiol ligand.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: April 1, 2014
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: Alexei G. Basnakian, Richard B. Walker, John R. J. Sorenson deceased, Anne S. Martin
  • Patent number: 8685433
    Abstract: The present invention provides an absorbable coating for an implantable device and the methods of making and using the same.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: April 1, 2014
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Lothar W. Kleiner, Syed F. A. Hossainy, Mikael Trollsas, Stephen D. Pacetti
  • Publication number: 20140011791
    Abstract: Methods for effective remyelination in patients are disclosed comprising treating the patient with an androgen receptor ligand which exerts binding to androgen receptors and elicits androgen-receptor-induced biological responses at a dosage sufficient to induce remyelination. The androgen compound preferably comprises MENT in an androgen targeting both androgen and estrogen receptors, and the methods include combining the androgen compound with a progestin compound in order to provide both contraception in men and treatment for neurodegeneration.
    Type: Application
    Filed: March 22, 2012
    Publication date: January 9, 2014
    Applicant: THE POPULATION COUNCIL, INC.
    Inventors: Regine Sitruk-Ware, Michael Maria Helmut Schumacher, Abdelmouman Ghoumari, Said Ghandour, Rashad Hussain, Bartosz Bielecki
  • Publication number: 20130331365
    Abstract: The present invention provides methods of preventing or delaying the development of cancer (e.g., breast cancer) in BRCA1 mutation positive patients by beginning progesterone receptor antagonist treatment at an early age (e.g., by age 35, 30, or 25). In certain embodiment, such early treatment is long-term treatment, which may substitute or delay a preventative ovariectomy, single or double mastectomy (e.g., in patients wishing to delay or avoid a mastectomy, or patients that cannot afford a mastectomy).
    Type: Application
    Filed: August 19, 2013
    Publication date: December 12, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Eva Y.H.P. Lee
  • Publication number: 20130303495
    Abstract: A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of the therapeutic agent by formulation with a lipophilic surfactant, a hydrophilic surfactant, one or more solubilizers and, optionally, digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.
    Type: Application
    Filed: March 15, 2013
    Publication date: November 14, 2013
    Inventors: Om Dhingra, James S. Bernstein
  • Patent number: 8580300
    Abstract: The invention relates to an effervescent tablet for preparing a mouth rinsing solution, wherein the effervescent tablet exhibits a high release rate of budesonide. A high availability of the active ingredient during use as a mouth rinsing solution on the inflamed mucosa of the upper digestive tract is thereby achieved. The advantage of the formulation according to the invention lies in the bioavailability comparable to oral forms of administration, which allows the formulation to be used safely over an extended period of time.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: November 12, 2013
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolf Wilhelm, Pröls Markus
  • Publication number: 20130224302
    Abstract: A minimally invasive controlled drug delivery system for delivering a particular drug or drugs to a particular location of the eye, the system including a porous film template having pores configured and dimensioned to at least partially receive at least one drug therein, and wherein the template is dimensioned to be delivered into or onto the eye.
    Type: Application
    Filed: March 29, 2013
    Publication date: August 29, 2013
    Applicant: The Regents of the University of California
    Inventor: The Regents of the University of California
  • Patent number: 8470371
    Abstract: Polymeric micellar clusters formed from amphiphilic carbohydrate polymers and their uses in formulating drugs is disclosed, and in particular the finding that amphiphilic carbohydrate polymers are capable of self assembling to form micellar clusters in which the carbohydrate amphiphiles aggregate into hierarchically organized micellar clusters of individual aggregates. The micellar clusters may be transformed into stable nanoparticles with drugs, especially hydrophobic drugs that have poor aqueous solubility, and may improve the transfer of hydrophobic drugs across biological barriers.
    Type: Grant
    Filed: August 8, 2007
    Date of Patent: June 25, 2013
    Assignee: University College London
    Inventors: Ijeoma F. Uchegbu, Andreas G. Schatzlein, Xueliang Hou
  • Patent number: 8404668
    Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: March 26, 2013
    Assignees: The Hospital for Sick Children, McMaster University
    Inventors: Don J. Mahuran, Michael B. Tropak, Justin D. Buttner, Jan E. Blanchard, Eric D. Brown
  • Publication number: 20130072466
    Abstract: Provided is a composition containing placenta extracts as active ingredients. Placenta extracts are natural substances extracted from placentas of livestock and show effects that can replace steroids and reduce adverse effects of steroids, so that placenta extracts have a wide range of applications including contraceptives, anti-osteoporosis drugs, anti-anemic drugs, therapeutic agents for wasting diseases of muscular atrophy, agents for treating sexual dysfunction, therapeutic agents for wounds, and adipocyte differentiation stimulating agents for improving meat quality of livestock, etc.
    Type: Application
    Filed: February 21, 2011
    Publication date: March 21, 2013
    Applicant: Industry-Academic Cooperation Foundation, Yeungnam University
    Inventors: In Ho Choi, Dong Mok Lee, Eun Ju Lee, Ki-Ho Lee, Yong-Pil Cheon, Tae-Hoon Chun
  • Patent number: 8377915
    Abstract: This invention relates to methods and compositions which are useful in the modulation of endogenous growth hormone levels in a mammal. Also included are methods of treating a mammal which include the administration of said compositions.
    Type: Grant
    Filed: May 2, 2007
    Date of Patent: February 19, 2013
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Jonathan Gorelick-Feldman, Ilya Raskin
  • Publication number: 20120283217
    Abstract: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.
    Type: Application
    Filed: July 16, 2012
    Publication date: November 8, 2012
    Applicant: SATORI PHARMACEUTICALS, INC.
    Inventors: Mark A. Findeis, Steffen P. Creaser
  • Publication number: 20120277199
    Abstract: Disclosed herein are methods for modulation of gel temperature of poloxamer-containing formulations. Also described herein are sustained release pharmaceutical formulations that gel upon contact with the body and are administered by direct application of these compositions and formulations onto or via perfusion into the targeted structure(s).
    Type: Application
    Filed: October 19, 2010
    Publication date: November 1, 2012
    Applicant: Otonomy, Inc.
    Inventors: Qiang Ye, Luis A. Dellamary, Fabrice Piu
  • Publication number: 20120258939
    Abstract: The present invention provides a method for preparing a sterile suspension of a glucocorticosteroid. The glucocorticosteroids used in the invention are preferably antiinflammatory glucocorticosteroids. By making the last stage of product preparation be the sterilization process, the potential for contamination during manufacture and heat degradation of products is greatly reduced.
    Type: Application
    Filed: April 16, 2012
    Publication date: October 11, 2012
    Applicant: Norton Healthcare Limited
    Inventors: John Miller, Donald MacDonald, Martin Oliver, Matthew Pollard, Paul Ronald, Adrian Ashley, Paul Lamb
  • Publication number: 20120225853
    Abstract: The treatment and/or prevention of depression by the co-administration of an estrogen with the progestin dienogest for HRT and/or contraception.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 6, 2012
    Applicant: BAYER PHARMA AG
    Inventors: Ina RUDOLPH, Thomas GRÄSER
  • Publication number: 20120177739
    Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
    Type: Application
    Filed: March 23, 2012
    Publication date: July 12, 2012
    Applicant: Jagotec AG
    Inventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
  • Publication number: 20120172344
    Abstract: Provided is an insulin-producing cell inducer, an enhancer for glucose intake of muscles, and a therapeutic agent for diabetes or diabetes complications, wherein an active ingredient of those provided is an estrogenic compound such as estrogen and estradiol. With the present invention, functions of insulin-producing cells can be recovered since the insulin-producing cells are induced in pancreatic ducts, and blood glucose level can be immediately lowered since glucose in the blood can be effectively taken up by muscles; therefore, diabetes and diabetes complications can be prevented or treated.
    Type: Application
    Filed: July 16, 2010
    Publication date: July 5, 2012
    Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventor: Akari Inada
  • Publication number: 20120142655
    Abstract: The present invention relates to novel crystalline Form II of 17?-acetoxy-21-methoxy-11?-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione, (also known as CDB-4124), processes for the preparation thereof and pharmaceutical compositions comprising it. Form II can be crystallized from different medium such as esters of C1-C4 alcohols and carboxylic acids, ketones, cyclohexane, acetonitrile, dimethylformamide, dimethyl sulfoxide, water and any mixture thereof.
    Type: Application
    Filed: August 5, 2010
    Publication date: June 7, 2012
    Inventors: Attila Balázs, János Csörgei, Ádám Demeter, Csaba Sánta
  • Publication number: 20120129823
    Abstract: A method for hormonal contraception comprising administering at least one contraceptive hormone in a plurality of linked taking periods optionally having a sequence lasting several years. Each taking period comprises at least one taking cycle. Each taking cycle comprises a duration-constant taking phase lasting several days and a taking pause lasting several days. In each taking phase the hormonal component is administrated in a daily unit. In each taking pause either a placebo or no unit is administered. The duration of the taking phase or phases of at least the final taking period is at least 22 days. The duration of each taking phase in any taking period preceding a following taking period is shorter than that in each of the taking phases in each following taking period.
    Type: Application
    Filed: December 12, 2011
    Publication date: May 24, 2012
    Inventor: Hermann KULMANN